InfuSystem Holdings, Inc.
Rank #16Capital ReturnINFU · NYSE · Healthcare
InfuSystem Holdings, Inc. (INFU) — Rank #16 by gross profitability (GP/assets 0.82) · ROE 11.2% · Piotroski F-Score 8 / 9.
As-of 2026-09-15 · CIK 0001337013 · all metrics point-in-time as of the filing date.
About
InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps and related products and services in the United States and Canada.
Show moreShow less
It operates through two segments: Patient Services and Device Solutions. The company supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. It also sells and rents new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, the company offers local and field-based customer support, as well as operates pump service and repair centers.
The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.
- Industry
- Medical Devices
- Sector
- Healthcare
- State
- DE
- Filer Category
- Accelerated filerSmaller reporting company
- Fiscal Year End
- December 31
- Website
- infusystem.com
Financials
Each fiscal year is read as-of that year’s own 10-K filing, so nothing restated after the fact leaks backwards. Line items this filer never tagged are omitted. Hover or tap a badge for the diagnostic behind it.
| Fiscal year end | 2025-12-31filed 2026-02-27 | 2024-12-31filed 2025-03-11 | 2023-12-31filed 2024-04-10 | 2022-12-31filed 2023-03-16 |
|---|---|---|---|---|
| Operating | ||||
| Depreciation & amortization | 13.3 | 12.5 | 12.5 | 13.4 |
| Stock-based compensation | 4.4 | 4.5 | 4.1 | 3.8 |
| Change in receivables | (0.3) | 0.7 | 2.4 | 1.2 |
| Change in inventory | (1.1) | 0.1 | 1.6 | 0.9 |
| Operating cash flow | 24.4 | 20.5 | 11.2 | 17.5 |
| Investing | ||||
| Capital expenditures | 0.6 | 1.1 | 1.0 | 1.0 |
| Acquisitions, net of cash | 1.4 | — | 0.0 | 0.0 |
| Investing cash flow | (6.8) | (13.2) | (6.7) | (11.5) |
| Financing | ||||
| Debt issued | — | — | — | — |
| Debt repaid | — | — | — | — |
| Share repurchases | 9.9 | 1.2 | 0.2 | 5.5 |
| Financing cash flow | (15.0) | (6.9) | (4.4) | (6.1) |
| Summary | ||||
| Free cash flow | 23.8 | 19.4 | 10.2 | 16.5 |
Figures are as originally filed with the SEC (point-in-time), not restated, so they can differ slightly from sites that show later-restated numbers. Why point-in-time?